These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37465316)

  • 1. Correlation analysis of circulating tumor cells and Claudin-4 in breast cancer.
    Chai J; Liu X; Hu X; Wang C
    Pathol Oncol Res; 2023; 29():1611224. PubMed ID: 37465316
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of epithelial-mesenchymal transition typing of circulating tumour cells in colorectal cancer.
    Hou J; Guo C; Lyu G
    Colorectal Dis; 2020 May; 22(5):581-587. PubMed ID: 31868956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.
    Yang X; Ni H; Lu Z; Zhang J; Zhang Q; Ning S; Qi L; Xiang B
    BMC Cancer; 2023 Jan; 23(1):10. PubMed ID: 36600214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY; Wu S; Ma X; Liu Y
    Breast Cancer Res Treat; 2024 Oct; 207(3):517-527. PubMed ID: 38990453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.
    Zhao L; Zheng Z; Liu Y; Liu F; Li X; Wu Z
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6035-6048. PubMed ID: 36633681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
    Szostakowska-Rodzos M; Fabisiewicz A; Wakula M; Tabor S; Szafron L; Jagiello-Gruszfeld A; Grzybowska EA
    Sci Rep; 2024 Jun; 14(1):12924. PubMed ID: 38839863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer.
    Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H
    Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer.
    Li W; Zhang X; Yang Y; Lin J; Zhou K; Sun R; Dang C; Diao D
    Sci Rep; 2024 Jun; 14(1):12758. PubMed ID: 38830909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.
    Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter
    Jin L; Zhao W; Zhang J; Chen W; Xie T; Wang L; Fan W; Xie S; Shen J; Zheng H; Hu W; Wei Q; Dong M; Wang Q; Shen J; Liu Y
    Cancer Med; 2020 Mar; 9(5):1638-1647. PubMed ID: 31908156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.
    Dirix L; Buys A; Oeyen S; Peeters D; Liègeois V; Prové A; Rondas D; Vervoort L; Mariën V; Laere SV; Vermeulen P
    Breast Cancer Res Treat; 2022 Jun; 193(2):437-444. PubMed ID: 35397078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.